Skip to content
AnalystLens

Insmed 8-K Report, Material Agreement (Feb 22, 2024)

Reports
Earnings & Results·Material Agreements·Exhibits & Filings
Filing Date
Filed February 22, 2024
Period End
February 22, 2024
Security
INSM
In the record · 2016–202610-K1110-Q338-K134

INSM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Leadership change8-K · May ’20May ’20
  3. Material agreement8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.

On February 22, 2024, Insmed Incorporated entered into a Sales Agreement with Leerink Partners LLC, as agent, under which the company may sell common stock having an aggregate offering price of up to $500,000,000a through an at-the-market offering.

Leerink receives a commission of 3.0% of gross proceeds, and the company is not obligated to sell any shares. The company intends to use net proceeds for ARIKAYCE commercialization and development, brensocatib research, development and pre-commercial and, if approved, commercialization activities, treprostinil palmitil inhalation powder development, and general corporate purposes. The agreement replaces a prior Leerink sales agreement from February 25, 2021 for up to $250,000,000,b which was terminated effective the same day with no termination penalties.

In the same filing, Insmed furnished a press release reporting fourth-quarter and full-year 2023 results. Total revenue was $83.7 millionc for the fourth quarter and $305.2 million for the full year, with full-year ARIKAYCE growth of 24%. The full-year net loss was $749.6 million, or $5.34 per share, and cash, cash equivalents and marketable securities totaled $780.4 million at December 31, 2023.

The company reiterated 2024 global ARIKAYCE revenue guidance of $340 million to $360 milliond, and said topline data from the Phase 3 ASPEN trial of brensocatib are expected in the latter part of the second quarter of 2024. For investors, the key points are the new $500 million equity capacity, which may dilute existing shareholders if used, alongside the company's large 2023 operating losses and near-term clinical catalysts, including the ASPEN and PH-ILD readouts expected in the second quarter of 2024.

02—Key points

Key Highlights

  1. Entered a Sales Agreement with Leerink Partners LLC allowing at-the-market sales of common stock of up to $500,000,000, with a 3.0% commission on gross proceeds
  2. Terminated the prior $250,000,000 Leerink sales agreement from February 25, 2021, effective February 22, 2024, with no termination penalties
  3. Full-year 2023 total revenue of $305.2 million, including $224.2 million in U.S. ARIKAYCE net sales, $65.7 million in Japan and $15.3 million in Europe and rest of world
  4. Full-year 2023 net loss of $749.6 million, or $5.34 per share, compared to a net loss of $481.5 million, or $3.91 per share, for 2022
  5. Cash, cash equivalents and marketable securities totaled $780.4 million as of December 31, 2023
  6. Reiterated 2024 global ARIKAYCE revenue guidance of $340 million to $360 million
  7. Topline data from the Phase 3 ASPEN trial of brensocatib in bronchiectasis remain on track for the latter part of the second quarter of 2024

03—Questions

Frequently Asked Questions

  1. How much stock can Insmed sell under the new sales agreement, and who is the agent?

    Insmed may offer and sell common stock with an aggregate offering price of up to $500,000,000 through Leerink Partners LLC, acting as agent. The company is not obligated to sell any shares.

  2. What does Insmed plan to use the proceeds for?

    The company intends to use any net proceeds to fund ARIKAYCE commercialization and development, brensocatib research and development and pre-commercial and, if approved, commercialization activities, treprostinil palmitil inhalation powder development, other research product candidates, and general corporate purposes including business expansion.

  3. What fees does Leerink receive for the sales?

    Insmed agreed to pay Leerink a commission equal to 3.0% of the gross proceeds from share sales under the agreement.

  4. What were Insmed's 2023 results?

    Total revenue for full-year 2023 was $305.2 million, up from $245.4 million in 2022. The net loss widened to $749.6 million, or $5.34 per share, from $481.5 million, or $3.91 per share. Research and development expenses were $571.0 million and SG&A expenses were $344.5 million.

  5. What key clinical events are expected in 2024?

    Insmed expects topline data from the Phase 3 ASPEN study of brensocatib in bronchiectasis in the latter part of the second quarter of 2024, and topline data from the Phase 2 PH-ILD study of TPIP in the second quarter of 2024, ahead of the ASPEN readout.

04—Continue

← View all 8-K filings